CytoSolve™ – In-Silico Drug Development
CytoSolve, Inc. is a start-up founded by two MIT scientists, V. A. Shiva Ayyadurai, PhD and C. Forbes Dewey Jr., PhD. CytoSolve™ has developed the world’s first computational platform for scalable integration of molecular pathway models. Our platform provides an important contribution to the field of Systems Biology. Using CytoSolve™, complex molecular pathway models have been tested and built for EGFR, nitric oxide and Interferon (IFN) pathways. Without CytoSolve™, the integration of complex molecular pathway models is largely manual, time-consuming and in many cases, not possible.
At CytoSolve, Inc., we use our platform for drug development in the fields of vaccines, liver cancer and heart disease. We also provide opportunities for commercial companies such as biotech and pharmaceutical companies to work with us to use the CytoSolve™ platform for supporting their internal drug development process.